Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefdinir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 11/20 | 0.84 |
| ▸ | MAPT | P10636 | 6/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.84 |
| ▸ | CNR1 | P21554 | 1/20 | 0.84 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.84 |
| ▸ | APEX1 | P27695 | 4/20 | 0.68 |
| ▸ | APAF1 | O14727 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.68 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.68 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.68 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.67 |
| ▸ | MMP2 | P08253 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefdinir SCHEMBL6090745 | 1.00 | TDP1 (0.84) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL10529476 | 0.98 | TDP1 (0.84) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL10529493 | 0.98 | TDP1 (0.84) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL1744290 | 0.92 | TDP1 (0.97) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL2532847 | 0.92 | TDP1 (0.97) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL16072816 | 0.92 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL3297328 | 0.92 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL1559599 | 0.92 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL36995 | 0.92 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL4114437 | 0.92 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006035291-A1 | CRYSTALLINE FORMS OF CEFDINIR POTASSIUM | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| US-20050080255-A1 | Reacting cefdinir with potassium compound; salt formation; crystallization from solvent | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-14 | — | — | US | disclosed |
| EP-1458728-A1 | CRYSTALLINE CEFDINIR POTASSIUM DIHYDRATE | Ranbaxy Laboratories Limited (IN) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003050124-A1 | CRYSTALLINE CEFDINIR POTASSIUM DIHYDRATE | RANBAXY LABORATORIES LIMITED (IN) | 2003-06-19 | — | — | WO | disclosed |
| EP-0105459-B1 | SYN-ISOMER OF 7-SUBSTITUTED-3-VINYL-3-CEPHEM COMPOUNDS, PROCESSES FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-22 | — | — | EP | disclosed |
| US-4559334-A | MICROBIOCIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-12-17 | — | — | US | disclosed |
| EP-0105459-A2 | Syn-isomer of 7-substituted-3-vinyl-3-cephem compounds, processes for production thereof and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080255-A1 | Reacting cefdinir with potassium compound; salt formation; crystallization from solvent | SPR, DCXR, KLK5 | TDP1 4590/4885MAPT 1393/4885ABCC4 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.